Show Notes
The NRG Oncology Podcast Co-hosts sit with NRG-BR008 "HERO" Study Co-PIs Dr. Lior Braunstein and Dr. Melissa Mitchell to discuss this study for low-risk HER2+ breast cancer. This study will test if HER2-targeted therapy without radiation therapy is as good as the usual treatment of HER2-targeted therapy with radiation for patients with early-stage HER2+ breast cancer.
More from The NRG Oncology Podcast
For Breast Cancer Awareness Month, we discuss the results of the NRG-BR002 in newly oligometastatic breast cancer published in the Journal of Clinical Oncology today.
We discuss the reported results of the NRG-HN009 p16-negative cohort presented at the ASTRO Annual Meeting Late-Breaking Abstract Session.
We discuss both the NRG-CC009 study results presented during the 2026 ASTRO Annual Meeting Plenary Session and the MAVERICK study results presented during the Clinical Trials Session.
We discuss the NRG-GI003 results presented during the 2026 ASTRO Annual Meeting Plenary Session.
We interview Dr. Shang "George" Zhao on the NRG-RTOG 0534 "SPPORT" study results he presented at the 2026 ASTRO Annual Meeting Clinical Trials Session.